Local recurrence and metastatic disease in pheochromocytomas and sympathetic paragangliomas.

Autor:	Araujo-Castro M; Endocrinology & Nutrition Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.; Instituto de Investigación Biomédica Ramón y Cajal (IRYCIS), Madrid, Spain., García Sanz I; General & Digestive Surgery Department, Hospital Universitario de La Princesa, Madrid, Spain., Mínguez Ojeda C; Urology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain., Hanzu F; Endocrinology & Nutrition Department, Hospital Clinic, Barcelona, Spain., Mora M; Endocrinology & Nutrition Department, Hospital Clinic, Barcelona, Spain., Vicente A; Endocrinology & Nutrition Department, Hospital Universitario de Toledo, Toledo, Spain., Blanco Carrera C; Endocrinology & Nutrition Department, Hospital Universitario Príncipe de Asturias, Madrid, Spain., de Miguel Novoa P; Endocrinology & Nutrition Department, Hospital Clínico San Carlos, Madrid, Spain., López García MDC; Endocrinology & Nutrition Department, Hospital Universitario de Albacete, Albacete, Spain., Lamas C; Endocrinology & Nutrition Department, Hospital Universitario de Albacete, Albacete, Spain., Manjón-Miguélez L; Endocrinology & Nutrition Department, Hospital Universitario Central de Asturias, Oviedo, Spain & Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain., Del Castillo Tous M; Endocrinology & Nutrition Department, Hospital Universitario Virgen de la Macarena, Sevilla, Spain., Rodríguez de Vera P; Endocrinology & Nutrition Department, Hospital Universitario Virgen de la Macarena, Sevilla, Spain., Barahona San Millán R; Endocrinology & Nutrition Department, Institut Català de la Salut Girona, Girona, Spain., Recasens M; Endocrinology & Nutrition Department, Institut Català de la Salut Girona, Girona, Spain., Tomé Fernández-Ladreda M; Endocrinology & Nutrition Department, Hospital Universitario de Puerto Real, Cádiz, Spain., Valdés N; Endocrinology & Nutrition Department, Hospital Universitario Cruces, Biobizkaia, Bizkaia, Spain., Gracia Gimeno P; Endocrinology & Nutrition Department, Hospital Royo Villanueva, Zaragoza, Spain., Robles Lazaro C; Endocrinology & Nutrition Department, Hospital Universitario de Salamanca, Salamanca, Spain., Michalopoulou T; Department of Endocrinology and Nutrition, Joan XXIII University Hospital, Tarragona, Spain., Álvarez Escolá C; Endocrinology & Nutrition Department, Hospital Universitario La Paz, Madrid, Spain., García Centeno R; Endocrinology & Nutrition Department, Hospital Universitario Gregorio Marañón, Madrid, Spain., Barca-Tierno V; Genetic Department, Hospital Universitario Ramón y Cajal, Madrid, Spain., Herrera-Martínez AD; Endocrinology & Nutrition Department, Hospital Reina Sofía, Córdoba, Spain., Calatayud M; Endocrinology & Nutrition Department, Hospital Universitario Doce de Octubre, Madrid, Spain.
Jazyk:	angličtina
Zdroj:	Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2023 Dec 07; Vol. 14, pp. 1279828. Date of Electronic Publication: 2023 Dec 07 (Print Publication: 2023).
DOI:	10.3389/fendo.2023.1279828
Abstrakt:	Purpose: To evaluate the rate of recurrence among patients with pheochromocytomas and sympathetic paragangliomas (PGLs; together PPGLs) and to identify predictors of recurrence (local recurrence and/or metastatic disease). Methods: This retrospective multicenter study included information of 303 patients with PPGLs in follow-up in 19 Spanish tertiary hospitals. Recurrent disease was defined by the development of local recurrence and/or metastatic disease after initial complete surgical resection. Results: A total of 303 patients with PPGLs that underwent 311 resections were included (288 pheochromocytomas and 15 sympathetic PGLs). After a median follow-up of 4.8 years (range 1-19), 24 patients (7.9%) had recurrent disease (3 local recurrence, 17 metastatic disease and 4 local recurrence followed by metastatic disease). The median time from the diagnosis of the PPGL to the recurrence was of 11.2 months (range 0.5-174) and recurrent disease cases distributed uniformly during the follow-up period. The presence of a pathogenic variant in SDHB gene (hazard ratio [HR] 13.3, 95% CI 4.20-41.92), higher urinary normetanephrine levels (HR 1.02 per each increase in standard deviation, 95% CI 1.01-1.03) and a larger tumor size (HR 1.01 per each increase in mm, 95% CI 1.00-1.02) were independently associated with disease recurrence. Conclusion: The recurrence of PPGLs occurred more frequently in patients with SDHB mutations, with larger tumors and with higher urinary normetanephrine levels. Since PPGL recurrence may occur at any time after the initial PPGL diagnosis is performed, we recommend performing a strict follow-up in all patients with PPGLs, especially in those patients with a higher risk of recurrent disease. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Araujo-Castro, García Sanz, Mínguez Ojeda, Hanzu, Mora, Vicente, Blanco Carrera, de Miguel Novoa, López García, Lamas, Manjón-Miguélez, del Castillo Tous, Rodríguez de Vera, Barahona San Millán, Recasens, Tomé Fernández-Ladreda, Valdés, Gracia Gimeno, Robles Lazaro, Michalopoulou, Álvarez Escolá, García Centeno, Barca-Tierno, Herrera-Martínez and Calatayud.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu